Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ("Innocan" or the "Company"), a pioneer in the ...

They work by blocking pain signals to the brain or interfering with the brain's interpretation of those signals. Analgesics are broadly categorized as being either non-opioid (non-narcotic) or opioid ...

UT Health San Antonio Multispecialty and Research Hospital is the first hospital in Texas to approve a non-narcotic ...

Use of the investigational non-opioid analgesic resiniferatoxin appeared to improve pain control in patients with advanced cancer who had intractable pain, though all patients experienced adverse ...

Over 200 adverse events were reported with a single injection of resiniferatoxin in 19 patients with refractory cancer pain. At least one adverse event occurred in all patients. Resiniferatoxin ...

Non-Opioid Analgesic Development Programs". Innocan's proprietary LPT-CBD platform is uniquely positioned to align with this regulatory focus. LPT-CBD is an innovative injectable liposomal drug ...